tetano
Editor, Senior Moderator
Front Immunol
. 2020 Oct 20;11:2172.
doi: 10.3389/fimmu.2020.02172. eCollection 2020.
Modulation of Immune Responses to Influenza A Virus Vaccines by Natural Killer T Cells
John P Driver[SUP] 1 [/SUP], Darling Melany de Carvalho Madrid[SUP] 1 [/SUP], Weihong Gu[SUP] 1 [/SUP], Bianca L Artiaga[SUP] 2 [/SUP], J?rgen A Richt[SUP] 2 [/SUP]
Affiliations
Abstract
Influenza A viruses (IAVs) circulate widely among different mammalian and avian hosts and sometimes give rise to zoonotic infections. Vaccination is a mainstay of IAV prevention and control. However, the efficacy of IAV vaccines is often suboptimal because of insufficient cross-protection among different IAV genotypes and subtypes as well as the inability to keep up with the rapid molecular evolution of IAV strains. Much attention is focused on improving IAV vaccine efficiency using adjuvants, which are substances that can modulate and enhance immune responses to co-administered antigens. The current review is focused on a non-traditional approach of adjuvanting IAV vaccines by therapeutically targeting the immunomodulatory functions of a rare population of innate-like T lymphocytes called invariant natural killer T (iNKT) cells. These cells bridge the innate and adaptive immune systems and are capable of stimulating a wide array of immune cells that enhance vaccine-mediated immune responses. Here we discuss the factors that influence the adjuvant effects of iNKT cells for influenza vaccines as well as the obstacles that must be overcome before this novel adjuvant approach can be considered for human or veterinary use.
Keywords: adjuvant; immune modulation; influenza A virus; natural killer T (NKT) cells; vaccines.
. 2020 Oct 20;11:2172.
doi: 10.3389/fimmu.2020.02172. eCollection 2020.
Modulation of Immune Responses to Influenza A Virus Vaccines by Natural Killer T Cells
John P Driver[SUP] 1 [/SUP], Darling Melany de Carvalho Madrid[SUP] 1 [/SUP], Weihong Gu[SUP] 1 [/SUP], Bianca L Artiaga[SUP] 2 [/SUP], J?rgen A Richt[SUP] 2 [/SUP]
Affiliations
- PMID: 33193296
- PMCID: PMC7606973
- DOI: 10.3389/fimmu.2020.02172
Abstract
Influenza A viruses (IAVs) circulate widely among different mammalian and avian hosts and sometimes give rise to zoonotic infections. Vaccination is a mainstay of IAV prevention and control. However, the efficacy of IAV vaccines is often suboptimal because of insufficient cross-protection among different IAV genotypes and subtypes as well as the inability to keep up with the rapid molecular evolution of IAV strains. Much attention is focused on improving IAV vaccine efficiency using adjuvants, which are substances that can modulate and enhance immune responses to co-administered antigens. The current review is focused on a non-traditional approach of adjuvanting IAV vaccines by therapeutically targeting the immunomodulatory functions of a rare population of innate-like T lymphocytes called invariant natural killer T (iNKT) cells. These cells bridge the innate and adaptive immune systems and are capable of stimulating a wide array of immune cells that enhance vaccine-mediated immune responses. Here we discuss the factors that influence the adjuvant effects of iNKT cells for influenza vaccines as well as the obstacles that must be overcome before this novel adjuvant approach can be considered for human or veterinary use.
Keywords: adjuvant; immune modulation; influenza A virus; natural killer T (NKT) cells; vaccines.